Transcatheter Tricuspid Valve Replacement for Severe Tricuspid Regurgitation (TRISCEND II trial)
Very sick patients took their risk up front with new procedure, and often benefited
Transcatheter aortic-valve replacement (TAVR) and mitral transcatheter edge-to-edge repair (M-TEER) have emerged as lower-morbidity options for selected patients with severe aortic stenosis or mitral regurgitation. Transcatheter tricuspid valve replacement has proved to be more challenging.
Edwards Lifesciences won FDA approval in February 2024 for its E…
Keep reading with a 7-day free trial
Subscribe to PulmCCM to keep reading this post and get 7 days of free access to the full post archives.